Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 375Gynecologic 268Gastrointestinal 228Thoracic 227Head & Neck 90Genitourinary 64Other solid neoplasm 29Tumor-Agnostic 24Sarcoma 24Dermatologic 21CNS 19Lymphoid 13Other hematologic neoplasm 9Endocrine 9Plasma cell 4Other neoplasm 3Other 3Classical hematology 2

Conditions

Triple Negative Breast Neoplasms 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Anemia 1

Interventions

Cyclophosphamide 79fludarabine phosphate 75Busulfan 53Whole-Body Irradiation 51Mycophenolic Acid 50Cyclosporine 47Peripheral Blood Stem Cell Transplantation 46fludarabine 42Antilymphocyte Serum 37Melphalan 36Tacrolimus 35Filgrastim 30Cord Blood Stem Cell Transplantation 27Radiotherapy 23Methotrexate 22Cytarabine 22Methylprednisolone 19Granulocyte Colony-Stimulating Factor 18apixaban 17Thiotepa 17Dalteparin 13thymoglobulin 12Rivaroxaban 12Alemtuzumab 12eltrombopag 11ferric carboxymaltose 10Surveys and Questionnaires 10Etoposide 10Epoetin Alfa 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Paclitaxel × Classical hematology × Clear all
NCT05485766 2025-03-20

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Okayama University

Phase 2 Recruiting
23 enrolled
BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00189371 2005-09-19

Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum

AGO Study Group

Phase 3 Terminated
300 enrolled
Classical hematologyGynecologic

Carcinoma, Ovarian Epithelial, Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡